Clinical Trial Update: Afatinib Expanded Access Program

View source ↗

Summary

Boehringer Ingelheim's Afatinib Expanded Access Program has been approved for marketing for non-small cell lung cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Afatinib (afatinib)

Snippet

Sponsor: Boehringer Ingelheim | Conditions: Carcinoma, Non-Small-Cell Lung | Status: APPROVED_FOR_MARKETING